Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Wednesday 04 December, 2019

Evgen Pharma PLC

Notice of Results

RNS Number : 7057V
Evgen Pharma PLC
04 December 2019

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")


Notice of results


Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it will issue its unaudited interim results for the six months ended 30 September 2019 on Tuesday, 17 December 2019.




Evgen Pharma plc 

via Walbrook 

Dr Stephen Franklin, CEO 

Richard Moulson, CFO 


+44 (0) 20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 

Alice Lane, Manasa Patil (ECM) 

WG Partners LLP 

+44 (0) 20 3705 9330 

Nigel Barnes / Claes Spång  

Walbrook PR 

+44 (0)20 7933 87870 or [email protected]

Paul McManus / Anna Dunphy 

+44 (0)7980 541 893 / +44 (0)7876 741 001 



About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  


The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 


For further information, please visit: 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t